• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel therapy targeting lipid rafts in multiple myeloma

Research Project

Project/Area Number 20591130
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionThe University of Tokushima

Principal Investigator

OZAKI Shuji  The University of Tokushima, 医学部・歯学部附属病院, 講師 (90314872)

Project Period (FY) 2008 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords血液内科学 / 造血器腫瘍 / 多発性骨髄腫 / 脂質ラフト / モノクローナル抗体
Research Abstract

HM1.24 and HM1.27 are specifically overexpressed in myeloma cells and monoclonal antibodies specific to these antigens induced myeloma cell death by aggregation of lipid rafts. These antibodies mediated cell death and inhibited colony formation of myeloma stem cells. These results suggest that the antibody therapy targeting lipids rafts will be an important strategy for the treatment of multiple myeloma.

Report

(4 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • 2008 Annual Research Report
  • Research Products

    (29 results)

All 2011 2010 2009 2008

All Journal Article (20 results) (of which Peer Reviewed: 19 results) Presentation (8 results) Book (1 results)

  • [Journal Article] Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.2011

    • Author(s)
      Ozaki S, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Matsumoto T.
    • Journal Title

      Int J Hematol 93

      Pages: 257-259

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.2011

    • Author(s)
      Ozaki S, et al.
    • Journal Title

      Int J Hematol

      Volume: 93 Pages: 257-259

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Size-controlled synthesis, surface functionalization, and biological applications of thiol-organosilica particles.2010

    • Author(s)
      Nakamura M, Ozaki S, Abe M, Doi H, Matsumoto T, Ishimura K.
    • Journal Title

      Colloids Surf B Biointerfaces 79

      Pages: 19-26

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth.2010

    • Author(s)
      Takeuchi K, Abe M, Hiasa M, Oda A, Amou H, Kido S, Harada T, Tanaka O, Miki H, Nakamura S, Nakano A, Kagawa K, Yata K, Ozaki S, Matsumoto T.
    • Journal Title

      PLoS ONE 5

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth.2010

    • Author(s)
      Takeuchi K, et al.
    • Journal Title

      PLoS ONE

      Volume: 5

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Size-controlled synthesis, surface functionalization, and biological applications of thiol-organosilica particles.2010

    • Author(s)
      Nakamura M, et al.
    • Journal Title

      Colloids Surf B Biointerfaces

      Volume: 79 Pages: 19-26

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).2009

    • Author(s)
      Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, Ozaki S, Asaoka K, Tanaka E, Moriyama K, Matsumoto T.
    • Journal Title

      Blood 114

      Pages: 4517-4526

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.2009

    • Author(s)
      Kodama T, Abe M, lida S, Ozaki S, Sakai A, Sawamura M, Shimazaki C, Miyata A, Wakayama T, Murakami H.
    • Journal Title

      Clin Lymphoma Myeloma 9

      Pages: 154-159

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.2009

    • Author(s)
      Wang W, Nishioka Y, Ozaki S, Jalili A, Abe S, Kakiuchi S, Kishuku M, Minakuchi K, Matsumoto T, Sone S.
    • Journal Title

      Cancer Immunol Immunother 58

      Pages: 967-976

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.2009

    • Author(s)
      Miki H, Ozaki S, Tanaka O, Lee E, Takimoto T, Watanabe H, Fujii S, Nakamura S, Kagawa K, Takeuchi K, Yata KI, Abe M, Kagami S, Matsumoto T.
    • Journal Title

      Int J Hematol 89

      Pages: 223-226

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-lalpha and MIP-lbeta production.2009

    • Author(s)
      Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T.
    • Journal Title

      J Bone Miner Metab 27

      Pages: 16-23

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Chimeric and humanized anti-HM1.24 antibodies mediate antibody- dependent cellular cytotoxicity against lung cancer cells.2009

    • Author(s)
      Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    • Journal Title

      Lung Cancer 63

      Pages: 23-31

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma2009

    • Author(s)
      Miki H, et al.
    • Journal Title

      Int J Hematol 89

      Pages: 223-226

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] HM1.24(CD317)is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody2009

    • Author(s)
      Wang W, et al.
    • Journal Title

      Cancer Immunol Immunother 58

      Pages: 967-976

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme(TACE)2009

    • Author(s)
      Hiasa M, et al.
    • Journal Title

      Blood 114

      Pages: 4517-4526

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article]2009

    • Author(s)
      Ozaki S
    • Journal Title

      Biologic therapies for multiple myeloma and plasma cell disorders. Emerging Protein Biotherapeutics(CRC Press)

      Pages: 267-279

    • Related Report
      2009 Annual Research Report
  • [Journal Article] Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.2009

    • Author(s)
      Wang w, et al.
    • Journal Title

      Lung Cancer 63

      Pages: 23-31

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-lalpha and MIP-1beta production.2009

    • Author(s)
      Abe M, et al.
    • Journal Title

      J Bone Miner Metab 27

      Pages: 16-23

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.2008

    • Author(s)
      Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.
    • Journal Title

      Cancer Sci 99

      Pages: 2461-2466

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograftmodels.2008

    • Author(s)
      Kawai S, et al.
    • Journal Title

      Cancer Sci 99

      Pages: 2461-2466

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Presentation] HLA class Iに特異的なsingle-chain Fv diabodyは骨髄腫細胞のside population分画に傷害を及ぼす2010

    • Author(s)
      池亀彰茂, 尾崎修治, 辻大輔, 原田武志, 中村信元, 三木浩和, 中野綾子, 賀川久美子, 竹内恭子, 矢田健一郎, 安倍正博, 伊藤孝司, 松本俊夫
    • Organizer
      第72回日本血液学会総会
    • Place of Presentation
      パシフィコ横浜
    • Related Report
      2010 Final Research Report
  • [Presentation] HLA class I-specific single-chain Fv diabody eradicates the side population fraction of myeloma cells2010

    • Author(s)
      池亀彰茂, ほか
    • Organizer
      第72回日本血液学会総会
    • Place of Presentation
      パシフィコ横浜(横浜市)
    • Related Report
      2010 Annual Research Report
  • [Presentation] 骨髄腫細胞のside populationを標的としたHLA class Iに特異的なscFv diabodyの抗腫瘍効果2009

    • Author(s)
      池亀彰茂, ほか
    • Organizer
      第71回日本血液学会総会
    • Place of Presentation
      国立京都国際会館(京都府)
    • Year and Date
      2009-10-23
    • Related Report
      2009 Annual Research Report
  • [Presentation] A recombinant HLA class I-specific single-chain Fv diabody can target cancer stem cell-like side population cells in multiple myeloma.2009

    • Author(s)
      Akishige Ikegame, Shuji Ozaki, Daisuke Tsuji, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, Masahiro Abe, Kohji Itoh, Toshio Matsumoto.
    • Organizer
      51^<th> Annual Meeting of the American Society of Hematology
    • Place of Presentation
      New Orleans, Louisiana, USA
    • Related Report
      2010 Final Research Report
  • [Presentation] 骨髄腫細胞のside populationを標的としたHLA class Iに特異的なscFv diabodyの抗腫瘍効果2009

    • Author(s)
      池亀彰茂, 尾崎修治, 辻大輔, 原田武志, 中村信元, 三木浩和, 中野綾子, 賀川久美子, 竹内恭子, 矢田健一郎, 安倍正博, 伊藤孝司, 松本俊夫
    • Organizer
      第71回日本血液学会総会
    • Place of Presentation
      国立京都国際会館
    • Related Report
      2010 Final Research Report
  • [Presentation] Spicamycin誘導体であるKRN5500は骨髄腫細胞と破骨細胞の増殖を抑制し, 抗腫瘍効果を発揮する2008

    • Author(s)
      三木浩和, ほか
    • Organizer
      第70回日本血液学会総会
    • Place of Presentation
      国立京都国際会館
    • Year and Date
      2008-10-12
    • Related Report
      2008 Annual Research Report
  • [Presentation] KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.2008

    • Author(s)
      Hirokazu Miki, Shuji Ozaki, Osamu Tanaka, Shingen Nakamura, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, Masahiro Abe, Toshio Matsumoto.
    • Organizer
      50^<th> Annual Meeting of the American Society of Hematology
    • Place of Presentation
      San Francisco, CA, USA
    • Related Report
      2010 Final Research Report
  • [Presentation] Spicamycin誘導体KRN5500は骨髄腫細胞とともに破骨細胞の生存を抑制し,抗腫瘍効果を発揮する2008

    • Author(s)
      三木浩和, 尾崎修治, 田中修, 藤井志朗, 中村信元, 賀川久美子, 竹内恭子, 坂井晃, 矢田健一郎, 安倍正博, 松本俊夫
    • Organizer
      第70回 日本血液学会総会
    • Place of Presentation
      国立京都国際会館
    • Related Report
      2010 Final Research Report
  • [Book] Emerging Protein Biotherapeutics.(Biologic therapies for multiple myeloma and plasma cell disorders.)2009

    • Author(s)
      Ozaki S.
    • Publisher
      Editor Iqbal S. Grewal, CRC Press, Boca Raton, FL, USA
    • Related Report
      2010 Final Research Report

URL: 

Published: 2008-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi